The Massachusetts General Hospital Neurological Clinical Research Institute (NCRI) and The ALS Assocation announce a call for Phase II clinical trial applications for novel, high potential treatments for ALS.
Phase II Clinical development of novel, high-potential treatments for people with ALS RFP
The MGH Neurological Clinical Research Institute (NCRI) and The ALS Association are pleased to announce a call for phase II clinical trial applications for novel, high-potential treatments in Amyotrophic Lateral Sclerosis. Potential Phase II clinical trials should include interventions that have both a pharmacodynamics marker that can measure whether pathway of interest has been affected and a plan to collect samples for biomarker studies. There is an urgent need for improved ALS therapies as there is currently only one FDA-approved treatment for the disease, riluzole (Rilutek®). This Request for Proposals (RFP) aims to expedite the development of new therapies to test in people with ALS.
To access the RFP, click here.
To access the Letter of Intent, click here.